AxoGen’s (AXGN) Overweight Rating Reiterated at Cantor Fitzgerald

On March 8, 2025, Cantor Fitzgerald reaffirmed its overweight rating on the shares of AxoGen (NASDAQ:AXGN) in a research report distributed to investors. They have set a price target of $24.00 for the medical equipment company.

Additionally, Canaccord Genuity Group recently raised their price target for AxoGen from $22.00 to $26.00 and assigned a "buy" rating in their report published on February 26th. Currently, five equity research analysts have issued a buy rating for the stock. According to MarketBeat data, AxoGen holds an average rating of "Buy" with a consensus target price set at $20.75.

AxoGen Price Performance

On the morning of March 8, 2025, shares of NASDAQ AXGN opened at $17.73. The company has experienced a low of $5.55 and a high of $21.00 over the past fifty-two weeks. The 50-day moving average stands at $17.90, while the 200-day moving average is at $15.26. With a market cap of approximately $786.22 million, AxoGen has a price-to-earnings ratio of -55.41 and a beta of 1.00. Its debt-to-equity ratio is 0.67, with a quick ratio of 2.47 and a current ratio of 3.74.

Insider Trading Activity

Recently, there have been some movements among insiders. Director Amy McBride Wendell sold 5,000 shares of AxoGen on March 3rd at an average price of $20.02, totaling a value of $100,100. Post-transaction, she now owns 97,899 shares, valued at roughly $1,959,937.98, which reflects a 4.86% reduction in her ownership. This transaction has been documented in a legal filing available through the SEC.

Institutional Investor Movements

Various institutional investors have made adjustments to their holdings in AxoGen recently. Geode Capital Management LLC increased its stake by 3.2% over the third quarter, now owning 1,010,508 shares worth $14,170,000 after acquiring an additional 31,612 shares. Meanwhile, FMR LLC significantly increased its holdings by 743.1% in the same quarter, bringing its total to 178,957 shares valued at $2,509,000 after adding 157,730 shares. Barclays PLC raised its position by 119.3%, now holding 72,036 shares worth $1,010,000. Similarly, State Street Corp increased its stake by 11.9%, acquiring an additional 95,051 shares and owning a total of 896,674 shares worth $12,571,000. Lastly, Principal Financial Group Inc. initiated a new position in AxoGen worth approximately $207,000. Overall, institutional investors currently hold 80.29% of the company’s stock.

AxoGen Overview

AxoGen, Inc., along with its subsidiaries, focuses on the development and commercialization of technologies aimed at peripheral nerve regeneration and repair. Their product range includes the Avance Nerve Graft, a processed human nerve allograft designed for bridging severed peripheral nerves, and the AxoGuard Nerve Connector and Nerve Protector, which are aids for nerve repair and protection.

AxoGen, Investment, Rating